To provide a state of the art review of intranasal antiviral drug delivery and to discuss current applications, adverse reactions, and future considerations in the management of coronavirus disease 2019 (COVID-19).
A structured search of the current literature was performed of dates up to and including April 2020. Search terms were queried as related to topics of antiviral agents and intranasal applications. A series of video conferences was convened among experts in otolaryngology, infectious diseases, public health, pharmacology, and virology to review the literature and discuss relevant findings.
Conclusions
Intranasal drug delivery for antiviral agents has been studied for many years. Several agents have broad-spectrum antiviral activity, but they still require human safety and efficacy trials prior to implementation. Intranasal drug delivery has potential relevance for future clinical trials in the settings of disease spread prevention and treatment of SARS-CoV-2 and other viral diseases.
Implications for Practice
Intranasal drug delivery represents an important area of research for COVID-19 and other viral diseases. The consideration of any potential adverse reactions is paramount.
ChinAWHChuJTSPereraMRA, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet. Published online April2, 2020. doi:10.1016/S2666-5247(20)30003-3
2.
AronsMMHatfieldKMReddySC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. Published online April24, 2020. doi:10.1056/NEJMoa2008457
3.
LytrasTDellisGFlountziA, et al. High prevalence of SARS-CoV-2 infection in repatriation flights to Greece from three European countries. J Travel Med. 2020;27(3):taaa054.
4.
NishiuraHKobayashiTMiyamaT, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154-155.
5.
HeXLauEHYWuP, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-675.
6.
CascellaMRajnikMCuomoADulebohnSCDi NapoliR. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls; 2020.
7.
FehrARPerlmanS. Coronaviruses: An Overview of Their Replication and Pathogenesis. Springer; 2015.
8.
ShereenMAKhanSKazmiABashirNSiddiqueR. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.
9.
ShangJYeGShiK, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224.
10.
ChanJF-WKokK-HZhuZ, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221-236.
11.
LoeffelholzMJTangY-W. Laboratory diagnosis of emerging human coronavirus infections—the state of the art. Emerg Microbes Infect. 2020;9:747-756.
12.
WangWXuYGaoR, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-1844.
13.
PittetDAllegranziBBoyceJ. The World Health Organization guidelines on hand hygiene in health care and their consensus recommendations. Infect Control Hosp Epidemiol. 2009;30:611-622.
14.
RabenauHFKampfGCinatlJDoerrHW. Efficacy of various disinfectants against SARS coronavirus. J Hosp Infect. 2005;61:107-111.
15.
SiddhartaAPfaenderSVielleNJ, et al. Virucidal activity of World Health Organization–recommended formulations against enveloped viruses, including Zika, Ebola, and emerging coronaviruses. J Infect Dis. 2017;215:902-906.
KratzelATodtDV’kovskiP, et al. Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. Emerg Infect Dis. 2020;26(7). doi:10.3201/eid2607.200915
18.
SteedLLCostelloJLohiaSJonesTSpannhakeEWNguyenS. Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic. Am J Infect Control. 2014;42:841-846.
19.
EggersM. Infectious disease management and control with povidone iodine. Infect Dis Ther. 2019;8:581-593.
RezapoorMNicholsonTTabatabaeeRMChenAFMaltenfortMGParviziJ. Povidone-iodine-based solutions for decolonization of nasal Staphylococcus aureus: a randomized, prospective, placebo-controlled study. J Arthroplasty. 2017;32:2815-2819.
22.
WadaHNojimaYOgawaS, et al. Relationship between virucidal efficacy and freeiodine concentration of povidone-iodine in buffer solution. Biocontrol Sci. 2016;21(1):21-27.
23.
KimJHRimmerJMradNAhmadzadaSHarveyRJ. Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol. 2015;129:S45-S50.
24.
RamezanpourMSmithJLPPsaltisAJWormaldPJVreugdeS. In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells. Int Forum Allergy Rhinol. Published online April6, 2020. doi:10.1002/alr.22575
25.
MadyLJKubikMWBaddourKSnydermanCHRowanNR. Consideration of povidone-iodine as a public health intervention for COVID-19: utilization as “personal protective equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncol. 2020;105:104724.
26.
Kirk-BayleyJCombesJSunkaraneniSChallacombeS. The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may reduce cross infection and protect healthcare workers. SSRN. Published online May4, 2020. doi:10.2139/ssrn.3563092
27.
ChoiWYParkCWSonKMCheonJS. Aspiration pneumonitis due to povidone-iodine aspiration during a facial bone fracture reduction operation. J Craniofac Surg. 2014;25(2):e172-e174.
MimozOSeguinS. Povidone iodine mouthwash, gargle, and nasal spray to reduce naso- pharyngeal viral load in patients with COVID-19. Accessed May 4, 2020. https://clinicaltrials.gov/ct2/show/NCT04371965
EcclesRWintherBJohnstonSLRobinsonPTrampischMKoelschS. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial. Respir Res. 2015;16:121.
33.
LudwigMEnzenhoferESchneiderS, et al. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res. 2013;14:124.
34.
GernJEMosserAGSwensonCA, et al. Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis. 2007;195:1137-1143.
35.
BrownCMNwokejiERascatiKLZachryWPhillipsGA. Development of the Burden of Prior Authorization of Psychotherapeutics (BoPAP) scale to assess the effects of prior authorization among Texas Medicaid providers. Adm Policy Ment Health. 2009;36:278-287.
36.
RenniePBowtellPHullDCharbonneauDLambkin-WilliamsROxfordJ. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Respir Res. 2007;8:38.
37.
RamalingamSGrahamCDoveJMorriceLSheikhA. A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci Rep. 2019;9:1015.
38.
RamalingamSCaiBWongJ, et al. Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid levels. Sci Rep. 2018;8:13630.
39.
KanjanawaseeDSeresirikachornKChitsuthipakornWSnidvongsK. Hypertonic saline versus isotonic saline nasal irrigation: systematic review and meta-analysis. Am J Rhinol Allergy. 2018;32:269-279.
40.
KampfGTodtDPfaenderSSteinmannE. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104:246-251.
41.
GoyalSMChanderYYezliSOtterJA. Evaluating the virucidal efficacy of hydrogen peroxide vapour. J Hosp Infect. 2014;86:255-259.
42.
MakJWYChanFKLNgSC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. Published online April24, 2020. doi:10.1016/S2468-1253(20)30122-9
43.
LehtinenMJHibberdAAMannikkoS, et al. Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge. Sci Rep. 2018;8:11411.
44.
KanmaniPCluaPVizoso-PintoMG, et al. Respiratory commensal bacteria Corynebacterium pseudodiphtheriticum improves resistance of infant mice to respiratory syncytial virus and streptococcus pneumoniae superinfection. Front Microbiol. 2017;8:1613.
45.
ZelayaHTadaAVizoso-PintoMG, et al. Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation-coagulation interactions and reduces influenza virus-associated pulmonary damage. Inflamm Res. 2015;64:589-602.
46.
RosenPLPalmerJNO’MalleyBW, Jr.CohenNA. Surfactants in the management of rhinopathologies. Am J Rhinol Allergy. 2013;27:177-180.
47.
NumataMMitchellJRTipperJL, et al. Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models. J Biol Chem. 2020;295:1704-1715.
48.
VoelkerDRNumataM. Phospholipid regulation of innate immunity and respiratory viral infection. J Biol Chem. 2019;294:4282-4289.
TurnerJHWuJDorminyCAChandraRK. Safety and tolerability of surfactant nasal irrigation. Int Forum Allergy Rhinol. 2017;7:809-812.
52.
KeményLKoreckA. Ultraviolet light phototherapy for allergic rhinitis. J Photochem Photobiol B. 2007;87:58-65.
53.
KoreckAICsomaZBodaiL, et al. Rhinophototherapy: a new therapeutic tool for the management of allergic rhinitis. J Allergy Clin Immunol. 2005;115:541-547.
54.
CingiCCakliHYazASonguMBalC. Phototherapy for allergic rhinitis: a prospective, randomized, single-blind, placebo-controlled study. Ther Adv Respir Dis. 2010;4:209-213.
55.
DulguerovN GNCourvoisierDLandisBNLacroixJSHauserC. Rhinophototherapy in chronic rhinosinusitis: a double blind randomized placebo-controlled trial. Rhinol J. 2017;55:106.
56.
KoreckASzechenyiAMoroczM, et al. Effects of intranasal phototherapy on nasal mucosa in patients with allergic rhinitis. J Photochem Photobiol B. 2007;89:163-169.
57.
MitchellDPanikerLSanchezG, et al. Molecular response of nasal mucosa to therapeutic exposure to broad-band ultraviolet radiation. J Cell Mol Med. 2010;14:313-322.
58.
ApuhanTTerziEHKüknerAGökÜ. Histopathological evaluation of the effect of intranasal phototherapy on nasal mucosa in rabbits. J Photochem Photobiol B. 2011;105:94-97.
59.
FujiiTKitamuraYMizuguchiH, et al. Effects of irradiation with narrowband-ultraviolet B on up-regulation of histamine H1 receptor mRNA and induction of apoptosis in HeLa cells and nasal mucosa of rats. J Pharmacol Sci. 2018;138:54-62.
60.
YurttasVŞereflicanMErkoçoğluMTerziEHKüknerAOralM. Histopathological effects of intranasal phototherapy and nasal corticosteroids in allergic rhinitis in a rabbit model. J Photochem Photobiol B. 2015;149:289-291.
61.
HusainQBanksCWoodworthBABleierBS. Lightening in a bottle: comparison of ultraviolet light to traditional sterilization in saline irrigations bottles. Int Forum Allergy Rhinol. 2020;10:53-58.
62.
KeilSDRaganIYonemuraSHartsonLDartNKBowenR. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang. Published online April20, 2020. doi:10.1111/vox.12937
63.
KraisslCJCimiottiJGMeleneyFL. Considerations in the use of ultraviolet radiation in operating rooms. Ann Surg. 1940;111:161-185.
64.
SetlowRBGristEThompsonKWoodheadAD. Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci U S A. 1993;90:6666-6670.
65.
BalasubramanianD. Ultraviolet radiation and cataract. J Ocul Pharmacol Ther. 2000;16:285-297.
66.
PonnaiyaBBuonannoMWelchDShuryakIRanders-PehrsonGBrennerDJ. Far-UVC light prevents MRSA infection of superficial wounds in vivo. PLoS One. 2018;13:e0192053.
67.
BuonannoMRanders-PehrsonGBigelowAW, et al. 207-nm UV light—a promising tool for safe low-cost reduction of surgical site infections. I: in vitro studies. PLoS One. 2013;8:e76968.
68.
WintherBBuchertDTurnerRBHendleyJOTschaikinM. Decreased rhinovirus shedding after intranasal oxymetazoline application in adults with induced colds compared with intranasal saline. Am J Rhinol Allergy. 2010;24:374-377.
69.
de WeerdNASamarajiwaSAHertzogPJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007;282:20053-20057.
70.
ZieglerCGKAllonSJNyquistSK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. Published online April27, 2020. doi:10.1016/j.cell.2020.04.035
71.
CinatlJMorgensternBBauerGChandraPRabenauHDoerrHW. Treatment of SARS with human interferons. Lancet. 2003;362:293-294.
72.
SunYJiangJTienPLiuWLiJ. IFN-lambda: a new spotlight in innate immunity against influenza virus infection. Protein Cell. 2018;9:832-837.
73.
LinHHuangLZhouJ, et al. Efficacy and safety of interferon-alpha2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial. Arch Virol. 2016;161:3073-3080.
74.
DjukanovicRHarrisonTJohnstonSL, et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections: a randomized trial. Am J Respir Crit Care Med. 2014;190:145-154.
75.
MengZWangTLiC, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv. Published online May7, 2020. doi:10.1101/2020.04.11.20061473
76.
DavidSIllumL. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet. 2003;42:1107-1128.
77.
WaysTMLauWKhutoryanskiyV. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers. 2018;10:267.
78.
HongS-SOhKTChoiH-GLimS-J. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019;11:540.
79.
BodrattiAAlexandridisP. Formulation of poloxamers for drug delivery. J Funct Biomater. 2018;9:11.
80.
SnidvongsKThanaviratananichS. Update on intranasal medications in rhinosinusitis. Curr Allergy Asthma Rep. 2017;17(7):47.
81.
DjupeslandPGSkrettingA. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv. 2012;25:280-289.
82.
HarveyRJDebnathNSrubiskiABleierBSchlosserRJ. Fluid residuals and drug exposure in nasal irrigation. Otolaryngol Head Neck Surg. 2009;141:757-761.
83.
AderibigbeBANakiT. Design and efficacy of nanogels formulations for intranasal administration. Molecules. 2018;23.
84.
DayalPShaikMSSinghM. Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci. 2004;93:1725-1742.
85.
WangXLiuGMaJ, et al. In situ gel-forming system: an attractive alternative for nasal drug delivery. Crit Rev Ther Drug Carrier Syst2013; 30(5): 411-34.
86.
GeisthoffUBlumARuppclassenMPlinkertP. Lipid-based nose ointment for allergic rhinitis. Otolaryngol Head Neck Surg. 2005;133:754-761.
87.
SkalnyARinkLAjsuvakovaO, et al. Zinc and respiratory tract infections: perspectives for COVID-19 (Review). Int J Mol Med. 2020;46(1):17-26.
88.
AlexanderTHDavidsonTM. Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. Laryngoscope. 2006;116(2):217-220.
